The text provided includes the financial statements and notes of Vertex Pharmaceuticals Incorporated for the three months ended March 31, 2021. It covers various aspects such as revenues, expenses, income from operations, comprehensive income, balance sheets, shareholders' equity, cash flows, fair value measurements, collaborative arrangements, stock-based compensation, share repurchase programs, income taxes, commitments, contingencies, and additional cash flow information. The company's financial activities like leveraging credit facilities, hedging, indemnifications, and other contingencies are also detailed, providing a comprehensive overview of Vertex Pharmaceuticals' financial position and operations during the specified period.
The text provided delves into the Management's Discussion and Analysis of Financial Condition and Results of Operations of a pharmaceutical company. The company focuses on developing medicines for serious diseases, particularly cystic fibrosis (CF) and other genetic disorders, and is expanding its pipeline into new disease areas. The company details its financial highlights, business updates related to CF and pipeline developments in various diseases. It also discusses investments in external innovation, the impact of COVID-19 on its operations, and strategic transactions, such as acquisitions, collaborations, and licensing agreements. Additionally, the text highlights the company's revenues, expenses, operational performance, liquidity, capital resources, and future capital requirements, emphasizing the importance of managing its capital structure. The discussion also covers contractual commitments, critical accounting policies and estimates, and recent accounting pronouncements.
The text states that the information required about quantitative and qualitative disclosures regarding market risk is incorporated by reference from the discussion in a specific section of the company's Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on February 11, 2021.
The passage discusses the evaluation of disclosure controls and procedures by management at the end of the period covered by the Quarterly Report on Form 10-Q, concluding that as of March 31, 2021, the disclosure controls and procedures were effective in providing reasonable assurance for accurate and timely information disclosure. There have been no material changes in the internal controls over financial reporting during the three months ended March 31, 2021.
The company is not currently involved in any significant legal proceedings.
The text outlines the presence of risk factors in the annual report, with no material changes, and emphasizes forward-looking statements related to financial performance, impact of COVID-19, clinical trials, drug development, acquisitions, collaborations, business development activities, and other aspects. It elaborates on various expectations and factors that could affect actual outcomes, highlighting uncertainties and potential risks. The statements are not guarantees of future performance, and updates will be made as necessary based on current views and assumptions, with a disclaimer urging caution in relying too heavily on these statements.
The text details the issuer's share repurchase program authorized by the Board of Directors in November 2020. The program, called the 2020 Share Repurchase Program, allowed up to $500.0 million of their common stock to be repurchased by December 31, 2022. By March 31, 2021, the issuer had repurchased the entire authorized amount under the program. The repurchases of securities during the first three months of 2021 are outlined, showing the total number of shares purchased, average price per share, and the approximate dollar value of shares that may still be purchased under the program. Repurchases were conducted through open market or privately negotiated transactions in compliance with Rule 10b5-1 plans and Securities and Exchange Commission requirements.
I'm sorry, but it seems like the text was not received. Could you please provide the text that needs to be summarized in one go?
I'm ready to receive all the parts of the text whenever you're ready to share them.
Paul Silva, the Senior Vice President and Chief Accounting Officer of the company, retired on April 30, 2021. Kristen Ambrose, previously the Senior Vice President of various functions within the company, will take over as the new Chief Accounting Officer effective May 1, 2021. Ambrose has a background in finance and accounting roles within the medical device industry, having worked at Boston Scientific Corporation before joining the current company. Prior to this, she was an accountant at Ernst & Young LLP and holds a B.S. degree from the University of Virginia and is a Certified Public Accountant.
The text provided includes a list of exhibits related to certifications under the Sarbanes-Oxley Act of 2002, along with XBRL Instance and Taxonomy extensions. The document also features signatures confirming the submission of the report, signed by Charles F. Wagner, Jr., the Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Incorporated as of April 30, 2021.
